▲ 1.58%
prev close
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Congressional Trades
10
All tracked trades
Members Trading
7
Unique members
Net Activity
+2
6 buys · 4 sells
Members Who Traded This Stock
10 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2025-09-23 | GILDGilead Sciences Inc | Sell | $1,001 - $15,000 | 174d ago | — | |
| 2025-05-05 | GILDGilead Sciences Inc | Buy | $1,001 - $15,000 | 331d ago | — | |
| 2025-04-16 | GILDGilead Sciences Inc | Sell | $1,001 - $15,000 | 323d ago | — | |
| 2025-03-10 | GILDGilead Sciences Inc | Buy | $1,001 - $15,000 | 356d ago | — | |
| 2025-03-07 | GILDGilead Sciences Inc | Buy | $1,001 - $15,000 | 357d ago | — | |
| 2024-10-29 | GILDGilead Sciences Inc | Buy | $1,001 - $15,000 | 202d ago | — | |
| 2023-09-26 | GILDGilead Sciences Inc | Buy | $1,001 - $15,000 | 875d ago | — | |
| 2023-07-12 | GILDGilead Sciences Inc | Sell | $15,001 - $50,000 | 963d ago | — | |
| 2023-03-06 | GILDGilead Sciences Inc | Buy | $15,001 - $50,000 | 1081d ago | — | |
| 2021-11-10 | GILDGilead Sciences Inc | Sell | $15,001 - $50,000 | 1308d ago | — |
2025-09-23
Valerie Hoyle
GILD
Amount
$1,001 - $15,000
Filed
174d ago
2025-05-05
Marjorie Taylor Greene
GILD
Amount
$1,001 - $15,000
Filed
331d ago
2025-04-16
John Boozman
GILD
Amount
$1,001 - $15,000
Filed
323d ago
2025-03-10
Carol Devine Miller
GILD
Amount
$1,001 - $15,000
Filed
356d ago
2025-03-07
Josh Gottheimer
GILD
Amount
$1,001 - $15,000
Filed
357d ago
2024-10-29
Valerie Hoyle
GILD
Amount
$1,001 - $15,000
Filed
202d ago
2023-09-26
Greg Stanton
GILD
Amount
$1,001 - $15,000
Filed
875d ago
2023-07-12
Daniel Goldman
GILD
Amount
$15,001 - $50,000
Filed
963d ago
2023-03-06
Daniel Goldman
GILD
Amount
$15,001 - $50,000
Filed
1081d ago
2021-11-10
Carol Devine Miller
GILD
Amount
$15,001 - $50,000
Filed
1308d ago
Recent News
Powered by Polygon.io
2 Defensive Dividend Payers Growing Fast on AI Demand
Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases
Bile Duct Cancer Market to Grow by $1.07 Billion During 2026-2030: Key Trends, Investment Opportunities and Competitive Strategies Analyzed
SK pharmteco to Host Innovations in Pharmaceutical Manufacturing Symposium in Cambridge, Massachusetts
Gilead Powers Up Its Inflammation Pipeline With Over $1.5 Billion Acquisition
Trade Timeline
Congressional activity, newest first
Valerie Hoyle
2025-09-23 · Sale
$1,001 - $15,000
Marjorie Taylor Greene
2025-05-05 · Purchase
$1,001 - $15,000
John Boozman
2025-04-16 · Sale
$1,001 - $15,000
Carol Devine Miller
2025-03-10 · Purchase
$1,001 - $15,000
Josh Gottheimer
2025-03-07 · Purchase
$1,001 - $15,000
Valerie Hoyle
2024-10-29 · Purchase
$1,001 - $15,000
Greg Stanton
2023-09-26 · Purchase
$1,001 - $15,000
Daniel Goldman
2023-07-12 · Sale
$15,001 - $50,000
Daniel Goldman
2023-03-06 · Purchase
$15,001 - $50,000
Carol Devine Miller
2021-11-10 · Sale
$15,001 - $50,000